{"protocolSection":{"identificationModule":{"nctId":"NCT00772954","orgStudyIdInfo":{"id":"H-030-010"},"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity","officialTitle":"A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of Two Doses of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18 - 55 Years)"},"statusModule":{"statusVerifiedDate":"2012-04","overallStatus":"TERMINATED","whyStopped":"Issues with CTM stability.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-03"},"primaryCompletionDateStruct":{"date":"2006-06","type":"ACTUAL"},"completionDateStruct":{"date":"2006-06","type":"ACTUAL"},"studyFirstSubmitDate":"2008-10-10","studyFirstSubmitQcDate":"2008-10-10","studyFirstPostDateStruct":{"date":"2008-10-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-03-13","resultsFirstSubmitQcDate":"2012-04-19","resultsFirstPostDateStruct":{"date":"2012-05-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-04-19","lastUpdatePostDateStruct":{"date":"2012-05-21","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This Phase I, randomized, placebo-controlled, double-blinded, dose ranging study to assess the safety, tolerability, and immunogenicity of 2 dose levels of C. difficile vaccine. Population: healthy male and female adults, 18 to 55 years old.","detailedDescription":"This was a Phase I, randomized, placebo-controlled, double-blinded, dose ranging study designed to assess the safety, tolerability, and immunogenicity of C. difficile vaccine. The study was conducted in healthy male and female adults, 18 to 55 years old. Subjects was randomly assigned on Day 0 to receive one of two doses of C. difficile vaccine (50 or 100 mcg) or placebo (vehicle control containing alum)."},"conditionsModule":{"conditions":["Clostridium Difficile Infection","Clostridium Difficile Diarrhea"],"keywords":["Clostridium difficile diarrhea","Clostridium difficile toxoid vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":36,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo vaccine group","type":"PLACEBO_COMPARATOR","description":"Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.","interventionNames":["Biological: Vaccine diluent buffer"]},{"label":"Clostridium Difficile Vaccine Group 1","type":"EXPERIMENTAL","description":"Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.","interventionNames":["Biological: Clostridium difficile toxoid vaccine (50 μg)"]},{"label":"Clostridium Difficile Vaccine Group 2","type":"EXPERIMENTAL","description":"Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.","interventionNames":["Biological: Clostridium difficile toxoid vaccine (100 μg)"]}],"interventions":[{"type":"BIOLOGICAL","name":"Vaccine diluent buffer","description":"0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.","armGroupLabels":["Placebo vaccine group"]},{"type":"BIOLOGICAL","name":"Clostridium difficile toxoid vaccine (50 μg)","description":"0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.","armGroupLabels":["Clostridium Difficile Vaccine Group 1"]},{"type":"BIOLOGICAL","name":"Clostridium difficile toxoid vaccine (100 μg)","description":"0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.","armGroupLabels":["Clostridium Difficile Vaccine Group 2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Reporting Treatment-Emergent Adverse Events Post-vaccination With One of Two Formulations of Clostridium Difficile Toxoid Vaccine or a Placebo Vaccine.","timeFrame":"Day 0 up to 70 days post first vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult males or females, 18 - 55 years in good general health\n\nExclusion Criteria:\n\n* Evidence of current C. difficile infection, as determined by a positive stool C. difficile cytotoxin assay at screening\n* Evidence of any previous antibiotic-associated diarrhea caused by any etiology including C. difficile that required medical intervention or medication\n* Active or inactive irritable bowel disease, chronic abdominal pain, chronic diarrhea of any etiology, or inflammatory bowel disease.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dennis N Morrison, D.O.","affiliation":"Bio-Kinetic Clinical Applications, Inc.","role":"PRINCIPAL_INVESTIGATOR"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 36 participants who met the inclusion, but no exclusion criteria were enrolled and vaccinated.","recruitmentDetails":"Participants were enrolled on 28 March 2006 in 2 clinical centers in the US.","groups":[{"id":"FG000","title":"Placebo Vaccine Group","description":"Participants received a dose of placebo (vaccine diluent) on Day 0 and Day 28."},{"id":"FG001","title":"Clostridium Difficile Toxoid Vaccine Group 1","description":"Participants received a dose of 50 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28."},{"id":"FG002","title":"Clostridium Difficile Toxoid Vaccine Group 2","description":"Participants received a dose of 100 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo Vaccine Group","description":"Participants received a dose of placebo (vaccine diluent) on Day 0 and Day 28."},{"id":"BG001","title":"Clostridium Difficile Toxoid Vaccine Group 1","description":"Participants received a dose of 50 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28."},{"id":"BG002","title":"Clostridium Difficile Toxoid Vaccine Group 2","description":"Participants received a dose of 100 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"36"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"36"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"38.3","spread":"12.98"},{"groupId":"BG001","value":"36.9","spread":"12.67"},{"groupId":"BG002","value":"30.0","spread":"8.57"},{"groupId":"BG003","value":"35.1","spread":"11.84"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"23"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"13"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"36"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Reporting Treatment-Emergent Adverse Events Post-vaccination With One of Two Formulations of Clostridium Difficile Toxoid Vaccine or a Placebo Vaccine.","populationDescription":"Safety assessments were on the safety population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 0 up to 70 days post first vaccination","groups":[{"id":"OG000","title":"Placebo Vaccine Group","description":"Participants received a dose of placebo (vaccine diluent) on Day 0 and Day 28."},{"id":"OG001","title":"Clostridium Difficile Toxoid Vaccine Group 1","description":"Participants received a dose of 50 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28."},{"id":"OG002","title":"Clostridium Difficile Toxoid Vaccine Group 2","description":"Participants received a dose of 100 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"}]}],"classes":[{"title":"Injection site pain","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"9"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"}]}]},{"title":"Blood potassium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}]},{"title":"Protein urine present","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}]},{"title":"White blood cell count increased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}]},{"title":"Diarrhoea","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}]},{"title":"White blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]},{"title":"Eosinophil count increased","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"Abdominal pain","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"Injection site erythema","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Red blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Injection site swelling","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}]},{"title":"Injection site warmth","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Malaise","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"Blood urea increased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Sinus congestion","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Urine ketone body present","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events data were collected from the day of vaccination 1 (Day 0) to up to 8 months post-vaccination.","eventGroups":[{"id":"EG000","title":"Placebo Vaccine Group","description":"Participants received a dose of placebo (vaccine diluent) on Day 0 and Day 28.","seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG001","title":"Clostridium Difficile Toxoid Vaccine Group 1","description":"Participants received a dose of 50 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28.","seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12},{"id":"EG002","title":"Clostridium Difficile Toxoid Vaccine Group 2","description":"Participants received a dose of 100 μg Clostridium difficile toxoid vaccine on Day 0 and Day 28.","seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":12},{"groupId":"EG001","numAffected":12,"numAtRisk":12},{"groupId":"EG002","numAffected":9,"numAtRisk":12}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"Protein urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"Eosinophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"Red blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Urine ketone body present","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":2,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":5,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":12},{"groupId":"EG002","numAffected":5,"numAtRisk":12}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":3,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Injection site hemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Blood calcium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Haematocrit decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Monocyte count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Shoulder pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Cervical dysplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":0,"numAtRisk":12}]},{"term":"Rosacea","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 8.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":12},{"groupId":"EG002","numAffected":1,"numAtRisk":12}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"This study was terminated early in light of issues with CTM stability. All other study procedures and visits were performed per protocol."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications"},"pointOfContact":{"title":"Medical Director","organization":"Sanofi Pasteur Inc.","email":"RegistryContactUs@sanofipasteur.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003015","term":"Clostridium Infections"}],"ancestors":[{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}